# Elenestinib

Source: https://onco.cc/drugs/elenestinib/  
OnCo record `elenestinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Elenestinib is an experimental small-molecule drug from Blueprint Medicines in phase 3 trials for systemic mastocytosis, with its target not yet stated publicly.

## Summary

Elenestinib (BLU-263) is a small-molecule drug developed by Blueprint Medicines. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT04910685 ((HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis), in systemic mastocytosis. The largest, NCT04910685, plans to enrol 534 participants with primary completion expected 2032-09-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: BLU-263
- Modality: small molecule
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of Elenestinib: https://clinicaltrials.gov/search?intr=BLU-263

## Connected records

- cancers: [Indolent and smouldering systemic mastocytosis](https://onco.cc/cancers/indolent-systemic-mastocytosis/), [Systemic mastocytosis](https://onco.cc/cancers/systemic-mastocytosis/)
- companies: [Sanofi](https://onco.cc/companies/sanofi/)
- trials: [(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis](https://onco.cc/trials/nct04910685/)

---
JSON: https://onco.cc/api/v1/entities/elenestinib.json